
Exact Sciences Corporation EXAS
Annual report 2025
added 02-13-2026
Exact Sciences Corporation Gross Profit 2011-2026 | EXAS
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Exact Sciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.26 B | 1.92 B | 1.76 B | 1.42 B | - | - | 660 M | 336 M | 187 M | 54.2 M | 14.9 M | -2.53 M | 4.14 M | 4.14 M | 4.14 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.26 B | -2.53 M | 664 M |
Quarterly Gross Profit Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 584 M | 562 M | 501 M | - | 491 M | 488 M | 446 M | - | - | - | - | - | - | - | - | 334 M | 319 M | 300 M | 272 M | 346 M | 293 M | 170 M | 246 M | 213 M | 166 M | 148 M | 119 M | 105 M | 88.3 M | 76 M | 67.4 M | 63.9 M | 51.8 M | 39.7 M | 31.4 M | 21.4 M | 15.9 M | 11.1 M | 5.78 M | 6.75 M | 5.1 M | 3.02 M | 54 K | -1.9 M | -924 K | 294 K | 294 K | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.03 M | 1.04 M | 1.03 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 584 M | -1.9 M | 132 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
2.84 B | $ 115.19 | 0.1 % | $ 35 B | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.14 | 0.44 % | $ 6.21 M | ||
|
Burning Rock Biotech Limited
BNR
|
364 M | $ 16.2 | 0.56 % | $ 174 M | ||
|
Aspira Women's Health
AWH
|
5.92 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 16.29 | 1.46 % | $ 868 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
400 K | $ 1.41 | 2.92 % | $ 1.88 M | ||
|
Interpace Biosciences
IDXG
|
24.1 M | $ 2.25 | -2.17 % | $ 9.95 M | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 23.05 | -0.35 % | $ 640 M | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 175.38 | -0.17 % | $ 8.69 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
246 M | $ 498.64 | 1.04 % | $ 14.4 B | ||
|
Danaher Corporation
DHR
|
14.5 B | $ 190.7 | 0.6 % | $ 136 B | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
Myriad Genetics
MYGN
|
577 M | $ 4.47 | 2.64 % | $ 414 M | ||
|
Illumina
ILMN
|
2.86 B | $ 122.51 | 1.3 % | $ 19.5 B | ||
|
NeoGenomics
NEO
|
314 M | $ 7.94 | 3.19 % | $ 1.02 B | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 14.95 | 3.57 % | $ 452 M | ||
|
Guardant Health
GH
|
144 M | $ 78.76 | 0.2 % | $ 9.87 B | ||
|
QIAGEN N.V.
QGEN
|
1.3 B | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
83.8 K | $ 2.77 | 2.97 % | $ 89.9 K | ||
|
Biomerica
BMRA
|
498 K | $ 2.07 | -3.19 % | $ 4.75 M | ||
|
Invitae Corporation
NVTA
|
98.7 M | - | - | $ 21.2 M | ||
|
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 28.27 | -0.12 % | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 107.75 | 0.88 % | $ 8.89 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 261.97 | 0.4 % | $ 21.8 B | ||
|
Natera
NTRA
|
127 M | $ 199.83 | 3.52 % | $ 19.7 B | ||
|
Senseonics Holdings
SENS
|
15.8 M | $ 6.67 | -0.15 % | $ 278 M | ||
|
Lantheus Holdings
LNTH
|
942 M | $ 80.99 | 0.5 % | $ 5.47 B | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 192.07 | 0.29 % | $ 21.3 B | ||
|
Soleno Therapeutics
SLNO
|
-58.5 K | $ 52.58 | -0.1 % | $ 2.67 B | ||
|
Neogen Corporation
NEOG
|
421 M | $ 9.19 | -2.46 % | $ 1.99 B | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 5.0 | 1.21 % | $ 3.94 M | ||
|
Organovo Holdings
ONVO
|
1.87 M | - | -2.3 % | $ 19.4 M |